S
Setsuo Utsunomiya
Publications - 12
Citations - 422
Setsuo Utsunomiya is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 5, co-authored 12 publications receiving 364 citations.
Papers
More filters
Journal ArticleDOI
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Tomoya Yokota,Takashi Ura,N. Shibata,Daisuke Takahari,Kohei Shitara,M. Nomura,C. Kondo,Ayako Mizota,Setsuo Utsunomiya,Kei Muro,Yasushi Yatabe +10 more
TL;DR: Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC, and the KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurring CRC.
Journal ArticleDOI
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
K. Shitara,Satoshi Yuki,D Tahahari,Masato Nakamura,C. Kondo,Takashi Tsuda,Takayuki Kii,Y Tsuji,Setsuo Utsunomiya,Daisuke Ichikawa,Ayumu Hosokawa,Atsushi Ishiguro,Daisuke Sakai,Shuichi Hironaka,Isao Oze,Keitaro Matsuo,Kei Muro +16 more
TL;DR: Dose-escalated wPTX in patients with pretreated AGC met the predefined threshold of primary end point, OS (P<0.3); however, it did not show a significantly longer OS, and progression-free survival was significantly better with dose escalation.
Journal ArticleDOI
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Kohei Shitara,Satoshi Yuki,Motoki Yoshida,Daisuke Takahari,Setsuo Utsunomiya,Tomoya Yokota,Yozo Sato,Yoshitaka Inaba,Masahiro Tajika,Hiroki Kawai,Hidekazu Yamaura,Mina Kato,Kentaro Yamazaki,Yoshito Komatsu,Kei Muro +14 more
TL;DR: Combination chemotherapy with biweekly cetuximab and irinotecan was effective for pretreated metastatic colorectal cancer with wild-type KRAS.
Journal ArticleDOI
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
Kohei Shitara,Tomoya Yokota,Daisuke Takahari,Takashi Shibata,Takashi Ura,Setsuo Utsunomiya,Yoshitaka Inaba,Hidekazu Yamaura,Yozo Sato,Mina Najima,Hiroki Kawai,Masahiro Tajika,Akira Sawaki,Yasushi Yatabe,Kei Muro +14 more
TL;DR: Combined irinotecan and cetuximab chemotherapy is effective for pretreated metastatic wild-type KRAS colorectal cancer.